Article Information
PubMed
Published By
History
- Received September 18, 2019
- Revision received July 20, 2020
- Accepted July 21, 2020
- Published online August 3, 2020.
Copyright & Usage
Copyright © 2020 Driscoll et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
Author Information
- Joseph R. Driscoll1,2,
- Tanya L. Wallace1,
- Kasra A. Mansourian2,
- William J. Martin1 and
- Elyssa B. Margolis2
- 1BlackThorn Therapeutics, San Francisco, CA 94103
- 2UCSF Weill Institute of Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA 94143
- Correspondence should be addressed to Elyssa B. Margolis at elyssa.margolis{at}ucsf.edu.
Author contributions
Author contributions: J.R.D., T.L.W., W.J.M., and E.B.M. designed research; J.R.D., K.A.M., and E.B.M. performed research; J.R.D., K.A.M., and E.B.M. analyzed data; J.R.D., T.L.W., W.J.M., and E.B.M. wrote the paper.
Disclosures
T.L.W. and W.J.M. are employees of and shareholders in BlackThorn Therapeutics, which is evaluating BTRX-246040 for the treatment of neurobehavioral disorders. All other authors declare no competing financial interests.
This work was supported by a sponsored research agreement from BlackThorn Therapeutics, Inc. to the University of California, San Francisco and the Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse Grant R01 DA042025.
Funding
HHS | NIH | National Institute on Drug Abuse (NIDA)
R01 DA042025
Other Version
- You are viewing the most recent version of this article.
- previous version (August 03, 2020).